US BANCORP \DE\ - RECURSION PHARMACEUTICALS IN ownership

RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 146 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.32 and the average weighting 2.3%.

Quarter-by-quarter ownership
US BANCORP \DE\ ownership history of RECURSION PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2024$5,325
-19.7%
710
+6.8%
0.00%
Q1 2024$6,630
+671.8%
665
+478.3%
0.00%
Q2 2023$859
-99.5%
115
-99.3%
0.00%
Q3 2022$172,000
+30.3%
16,2000.0%0.00%
Q2 2022$132,00016,2000.00%
Other shareholders
RECURSION PHARMACEUTICALS IN shareholders Q3 2022
NameSharesValueWeighting ↓
Data Collective IV GP, LLC 5,941,120$45,806,03548.11%
Kinnevik AB (publ) 7,653,061$59,005,10033.28%
MV Management XI, L.L.C. 1,971,908$15,203,41126.45%
MIC Capital Management UK LLP 8,451,758$65,163,05712.86%
ArchPoint Investors 1,114,626$8,593,7664.07%
HARVARD MANAGEMENT CO INC 1,509,254$11,636,3481.44%
PLATINUM INVESTMENT MANAGEMENT LTD 2,710,339$20,896,7140.80%
Duquesne Family Office 1,385,950$10,685,6750.53%
ALLEN OPERATIONS LLC 217,657$1,678,1350.45%
Artal Group S.A. 960,204$7,4030.41%
View complete list of RECURSION PHARMACEUTICALS IN shareholders